Ovarian Serous Adenocarcinoma — Clinical Trials

MONDO:000521131 active·13 recruitingLast updated: Mar 19, 2026, 3:47 AM

Trial Landscape

Ovarian Serous Adenocarcinoma has an active clinical trial landscape, driven by drug treatment and biological therapy.

Recruiting

Active Trials

By Approach

Drug Treatment27

Biological Therapy13

Procedure10

Medical Device1

Gene Therapy1

13 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Early Phase 1

Phase 1

Phase 2

Phase 3

5 trials are observational or have no phase designation.

Sponsor Types

Academic/Other19Industry12NIH5

Top Sponsors

Scancell Ltd

Trial Locations

United States26 trials

Canada8 trials

Italy6 trials

South Korea4 trials

Belgium3 trials

Spain3 trials

China3 trials

France2 trials

United Kingdom2 trials

India2 trials

Trials often recruit across multiple countries, so totals exceed the trial count.

36 Trials

Phase 3Recruiting

NCT04575935

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Aug 2020Est. completion: Dec 2028Updated: Mar 2026

Phase 3Recruiting

NCT05601700

Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)

Sponsor:Ente Ospedaliero Ospedali Galliera

ItalyStarted: Sep 2022Est. completion: Sep 2029Updated: Jan 2025

Phase 2Recruiting

NCT05231122

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Sponsor:Roswell Park Cancer Institute

United StatesStarted: Mar 2024Est. completion: Dec 2026Updated: Mar 2026

Phase 2Recruiting

NCT06494150

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

Sponsor:University of Oklahoma

United StatesStarted: Dec 2024Est. completion: Sep 2029Updated: Feb 2026

Phase 2Recruiting

NCT04919629

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Sponsor:Roswell Park Cancer Institute

United StatesStarted: Apr 2023Est. completion: Apr 2027Updated: May 2025

Phase 1Recruiting

NCT05902988

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Sponsor:Volastra Therapeutics, Inc.

United StatesStarted: Oct 2023Est. completion: Dec 2026Updated: Nov 2025

Phase 1Recruiting

NCT05329532

Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

Sponsor:Scancell Ltd

United KingdomStarted: Apr 2022Est. completion: Jul 2027Updated: Sep 2025

Phase 1Recruiting

NCT06451497

Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Sponsor:Zumutor Biologics Inc.

United StatesStarted: May 2024Est. completion: Apr 2027Updated: Dec 2024

Early Phase 1Recruiting

NCT05415709

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Sponsor:Ohio State University Comprehensive Cancer Center

United StatesStarted: Jun 2022Est. completion: Dec 2026Updated: Feb 2026

Recruiting

NCT00488878

Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: May 2006Est. completion: May 2035Updated: Feb 2026

Phase 3Active, Not Recruiting

NCT01167712

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Sep 2010Est. completion: Jul 2026Updated: Mar 2026

Phase 3Active, Not Recruiting

NCT00565851

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Dec 2007Est. completion: Jan 2028Updated: Dec 2025

Phase 3Active, Not Recruiting

NCT04498117

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Sponsor:CanariaBio Inc.

United StatesStarted: Aug 2020Est. completion: Aug 2028Updated: Jul 2025

Phase 2Active, Not Recruiting

NCT04034927

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Dec 2019Est. completion: Feb 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT02502266

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2016Est. completion: Dec 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT05114421

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Nov 2021Est. completion: Jan 2026Updated: Aug 2025

Phase 2Active, Not Recruiting

NCT05605535

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Sponsor:CanariaBio Inc.

IndiaStarted: Feb 2023Est. completion: Sep 2027Updated: Jul 2025

Phase 1Active, Not Recruiting

NCT03586661

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Apr 2019Est. completion: Dec 2026Updated: Mar 2026

Phase 1Active, Not Recruiting

NCT01116648

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Apr 2010Est. completion: Nov 2026Updated: Mar 2026

Phase 1Active, Not Recruiting

NCT05527184

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

Sponsor:AbbVie

United StatesStarted: Jan 2023Est. completion: Feb 2027Updated: Feb 2026

Stay informed about clinical trials for Ovarian Serous Adenocarcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 19, 2026 at 3:47 AM

Ovarian Serous Adenocarcinoma — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Top Sponsors

Trial Locations

36 Trials

Open Trials16

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors

Active Trials15

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

Other5